Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VV5X
|
|||
| Former ID |
DIB006014
|
|||
| Drug Name |
EZN-3920
|
|||
| Synonyms |
SPC-3920; ERBB3 RNA inhibitor (cancer), Enzon/Santaris
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Investigative | [1] | |
| Company |
Santaris Pharma A/S
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ERBB3 messenger RNA (ERBB3 mRNA) | Target Info | Inhibitor | [1] |
| KEGG Pathway | ErbB signaling pathway | |||
| Calcium signaling pathway | ||||
| Endocytosis | ||||
| Proteoglycans in cancer | ||||
| MicroRNAs in cancer | ||||
| NetPath Pathway | TNFalpha Signaling Pathway | |||
| Panther Pathway | Cadherin signaling pathway | |||
| EGF receptor signaling pathway | ||||
| Pathway Interaction Database | ErbB2/ErbB3 signaling events | |||
| ErbB receptor signaling network | ||||
| a6b1 and a6b4 Integrin signaling | ||||
| WikiPathways | ErbB Signaling Pathway | |||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
| Signaling Pathways in Glioblastoma | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| Heart Development | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models. Mol Cancer Ther. 2013 Apr;12(4):427-37. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.